Onconova Therapeutics Inc
ONTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.22M
Close$
$0.86
96.4% downside
Current Fair Value
96.4% downsideOvervalued by 96.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.22 Million |
|---|---|
| Enterprise Value | $-1,911,951.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 0 |
| Outstanding Shares | - |
Return
| Return on Equity | -172367.12% |
|---|---|
| Return on Assets | 112241.52% |
| Return on Invested Capital | 435.53% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | 0.46 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.67 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Onconova Therapeutics Inc
CEO: Steven Fruchtman